Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution
暂无分享,去创建一个
J. Sanz | J. de la Rubia | I. Gómez-Seguí | P. Solves | J. Montoro | Marta Villalba | Ana Facal | Guillermo Sanz | M. Sanz | Javier Marco-Ayala | Aitana Balaguer-Roselló
[1] Yonggoo Kim,et al. Transfusion support in hematopoietic stem cell transplantation , 2023, Blood research.
[2] M. Sanz,et al. IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. , 2023, Transplantation and cellular therapy.
[3] C. Solano,et al. Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia , 2022, Bone Marrow Transplantation.
[4] Andrew D. Johnson,et al. International Forum on Transfusion Practices in Haematopoietic Stem‐Cell Transplantation: Summary , 2021, Vox sanguinis.
[5] J. Antin,et al. GVHD Prophylaxis 2020 , 2021, Frontiers in Immunology.
[6] C. Karanes,et al. Red blood cell and platelet transfusion support in the first 30 and 100 days after allogeneic hematopoietic cell transplant , 2020, Transfusion.
[7] E. Albert,et al. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors , 2020, Bone Marrow Transplantation.
[8] D. Allan,et al. Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Sanz,et al. Comparison of transfusion requirements in adult patients undergoing Haploidentical or single‐unit umbilical cord blood stem cell transplantation , 2019, European journal of haematology.
[10] C. Cohn,et al. Red blood cell product utilization in patients undergoing allogeneic stem cell transplantation , 2019, Transfusion.
[11] A. Barrett,et al. Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993–2010): factors that predict intensity and time to transfusion independence , 2018, Transfusion.
[12] J. Seghatchian,et al. Transfusion challenges in hematology oncology and hematopoietic stem cell transplant - Literature review and local experience. , 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[13] M. Sanz,et al. ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation , 2017, Bone Marrow Transplantation.
[14] A. Avdić,et al. Comparing the ratio of mean red blood cell transfusion episode rate of 1 unit versus 2 units in hematopoietic stem cell transplant patients , 2016, Transfusion.
[15] P. Chevallier,et al. Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation , 2016, Bone Marrow Transplantation.
[16] J. Sanz,et al. Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS , 2016, Bone Marrow Transplantation.
[17] D. Weisdorf,et al. Blood transfusions and pulmonary complications after hematopoietic cell transplantation , 2016, Transfusion.
[18] D. Purtill,et al. Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation , 2015, Internal medicine journal.
[19] M. Sanz,et al. Effect of CD8⁺ cell content on umbilical cord blood transplantation in adults with hematological malignancies. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[21] Q. Ran,et al. Clinical Observation of Factors in the Efficacy of Blood Component Transfusion in Patients following Hematopoietic Stem Cell Transplantation , 2012, PloS one.
[22] D. Weisdorf,et al. Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[23] M. Sorror,et al. The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation , 2010, British journal of haematology.
[24] A. Ganser,et al. TRANSPLANTATION AND CELLULAR ENGINEERING: Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk , 2009, Transfusion.
[25] J. Gajewski,et al. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. , 2008, Blood.
[26] S. Asano,et al. Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan , 2007, Bone Marrow Transplantation.
[27] P. Rebulla,et al. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. , 2004, The Cochrane database of systematic reviews.
[28] P. Sperryn,et al. Blood. , 1989, British journal of sports medicine.
[29] C. Cohn. Transfusion support issues in hematopoietic stem cell transplantation. , 2015, Cancer control : journal of the Moffitt Cancer Center.